MX2020011814A - Anticuerpo anti-tlr7 humano. - Google Patents

Anticuerpo anti-tlr7 humano.

Info

Publication number
MX2020011814A
MX2020011814A MX2020011814A MX2020011814A MX2020011814A MX 2020011814 A MX2020011814 A MX 2020011814A MX 2020011814 A MX2020011814 A MX 2020011814A MX 2020011814 A MX2020011814 A MX 2020011814A MX 2020011814 A MX2020011814 A MX 2020011814A
Authority
MX
Mexico
Prior art keywords
tlr7
human anti
tlr7 antibody
antibody
human
Prior art date
Application number
MX2020011814A
Other languages
English (en)
Inventor
Takashi Isobe
Takashi Kagari
Toshiyuki Shimizu
Kensuke Nakamura
Kensuke Miyake
Yusuke Murakami
Yuji Motoi
Atsuo Kanno
Umeharu Ohto
Takaichi Shimozato
Atsushi Manno
Jun Ishiguro
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MX2020011814A publication Critical patent/MX2020011814A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)

Abstract

La presente invención proporciona una composición farmacéutica que comprende un anticuerpo el cual se une específicamente a TLR7 humano o TLR7 de mono y no se une a TLR7 de ratón o TLR7 de rata, y tiene una actividad de inhibir una función de TLR7 humano o TLR7 de mono, y similares.
MX2020011814A 2018-05-31 2019-05-30 Anticuerpo anti-tlr7 humano. MX2020011814A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018104676 2018-05-31
PCT/JP2019/021466 WO2019230869A1 (ja) 2018-05-31 2019-05-30 抗ヒトｔｌｒ７抗体

Publications (1)

Publication Number Publication Date
MX2020011814A true MX2020011814A (es) 2020-12-07

Family

ID=68697552

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011814A MX2020011814A (es) 2018-05-31 2019-05-30 Anticuerpo anti-tlr7 humano.

Country Status (17)

Country Link
US (3) US11091560B2 (es)
EP (1) EP3805389A4 (es)
JP (4) JP6790307B2 (es)
KR (2) KR102729319B1 (es)
CN (3) CN112204143B (es)
AU (1) AU2019279206B2 (es)
BR (1) BR112020021266A2 (es)
CA (1) CA3099900A1 (es)
CO (1) CO2020015124A2 (es)
IL (2) IL278962B2 (es)
MX (1) MX2020011814A (es)
MY (1) MY208015A (es)
PH (1) PH12020551985A1 (es)
SG (1) SG11202010939WA (es)
TW (3) TWI875486B (es)
WO (1) WO2019230869A1 (es)
ZA (1) ZA202006903B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020021266A2 (pt) * 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano
WO2021146383A1 (en) * 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells
WO2026067859A1 (zh) * 2024-09-30 2026-04-02 北京森妙生物科技有限公司 一种抗tlr7抗体或其抗原结合片段、药物组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
NZ534666A (en) * 2000-05-25 2006-01-27 Schering Corp Mammalian DNAX Toll-like receptor protein, DTLR9, antibodies and medicaments made therefrom and use in treating immunological disorders
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
SI1583830T1 (sl) 2003-01-07 2006-12-31 Symphogen As Postopek za pripravo rekombinantnih poliklonskih proteinov
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
BRPI0818437B8 (pt) 2007-10-11 2021-05-25 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
WO2010054288A2 (en) * 2008-11-07 2010-05-14 National Jewish Health Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs")
MX343049B (es) 2009-04-09 2016-10-21 Daiichi Sankyo Co Ltd Anticuerpo anti-lectina similar a inmunoglobulina de union a acido sialico-15.
EP2470656B1 (en) * 2009-08-27 2015-05-06 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
JP5921535B2 (ja) * 2010-06-16 2016-05-24 ディナバックス テクノロジーズ コーポレイション Ｔｌｒ７および／またはｔｌｒ９阻害剤を用いる治療の方法
IN2014DN06806A (es) 2012-02-10 2015-05-22 Univ Maryland
WO2017004144A1 (en) * 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
US10370451B2 (en) 2013-04-22 2019-08-06 The University Of Tokyo Preventive or therapeutic agent for inflammatory disease
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
JP6980980B2 (ja) * 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
DK3354729T5 (da) * 2015-09-24 2024-09-30 Daiichi Sankyo Co Ltd Anti-garp-antistof
JP6949012B2 (ja) * 2015-10-09 2021-10-13 シャアメン ユニバーシティ Ｂ型肝炎表面抗原に対する抗体及びその使用
BR112020021266A2 (pt) * 2018-05-31 2021-01-26 Daiichi Sankyo Company, Limited anticorpo anti-tlr7 humano

Also Published As

Publication number Publication date
AU2019279206B2 (en) 2025-06-26
CN112204143B (zh) 2024-03-08
CO2020015124A2 (es) 2020-12-21
JP2021035378A (ja) 2021-03-04
TWI833761B (zh) 2024-03-01
JP6790307B2 (ja) 2020-11-25
EP3805389A1 (en) 2021-04-14
IL318087A (en) 2025-02-01
KR20210018192A (ko) 2021-02-17
US11578138B2 (en) 2023-02-14
IL278962A (en) 2021-01-31
IL278962B2 (en) 2025-06-01
TW202521585A (zh) 2025-06-01
US20210040225A1 (en) 2021-02-11
WO2019230869A1 (ja) 2019-12-05
IL278962B1 (en) 2025-02-01
US11091560B2 (en) 2021-08-17
MY208015A (en) 2025-04-07
KR102729319B1 (ko) 2024-11-11
CA3099900A1 (en) 2019-12-05
TWI875486B (zh) 2025-03-01
ZA202006903B (en) 2022-03-30
CN112204143A (zh) 2021-01-08
NZ770866A (en) 2025-07-25
SG11202010939WA (en) 2020-12-30
AU2019279206A1 (en) 2020-12-03
CN118126183A (zh) 2024-06-04
KR20240162605A (ko) 2024-11-15
PH12020551985A1 (en) 2021-08-02
TW202000704A (zh) 2020-01-01
JPWO2019230869A1 (ja) 2021-02-12
US20230212306A1 (en) 2023-07-06
US20210332149A1 (en) 2021-10-28
AU2019279206A2 (en) 2021-01-14
TW202428618A (zh) 2024-07-16
JP2026016483A (ja) 2026-02-03
JP2024012394A (ja) 2024-01-30
JP7377185B2 (ja) 2023-11-09
EP3805389A4 (en) 2022-03-23
CN118126182A (zh) 2024-06-04
KR102902330B1 (ko) 2025-12-18
BR112020021266A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
MX2019007347A (es) Anticuerpo anti-cd3 y moleculas que comprenden el anticuerpo.
SA520420801B1 (ar) أil جسام مضادة لـ -11
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
PH12020551985A1 (en) Anti-human tlr7 antibody
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
PH12020551716A1 (en) Anti-ror antibody constructs
EA201792583A1 (ru) Способы и композиции для ингибирования взаимодействия менина с белками mll
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
EA202191175A1 (ru) Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
CL2020003083A1 (es) Inhibidores de masp-2 y métodos de uso
EP4372002A3 (en) Proximity-based sortase-mediated protein purification and ligation
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021004331A (es) Composiciones estables de semaglutida y usos de las mismas.
EA201991511A1 (ru) Кристаллическая структура гремлин-1 и ингибирующее антитело
MX2023014154A (es) Anticuerpos anti-ccr8.
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1
EA201792262A1 (ru) Пироглутамат вортиоксетина
EA202090732A1 (ru) Составы для трансдермального введения
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
TR201914043A1 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari